Compile Data Set for Download or QSAR
maximum 50k data
Found 470 with Last Name = 'lockman' and Initial = 'j'
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309411((2S,3aS,4R,9bS)-N-benzyl-12- (cyclopropylmethyl)-3...)
Affinity DataKi:  0.0830nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309329((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- N-(2-guani...)
Affinity DataKi:  0.0980nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309331((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- N-(4-guani...)
Affinity DataKi:  0.130nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309413((2S,3aS,4R,9bS)-12-(cyclopropylmethyl)- 3a,8-dihyd...)
Affinity DataKi:  0.160nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309366((2R,3aS,4R,9bS)-methyl-12- (cyclopropylmethyl)-3a,...)
Affinity DataKi:  0.300nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataKi:  0.320nM ΔG°:  -54.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataKi:  0.330nM ΔG°:  -54.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309414((2S,3aS,4R,9bS)-12-(cyclopropylmethyl)- N-(2,4-dih...)
Affinity DataKi:  0.370nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309414((2S,3aS,4R,9bS)-12-(cyclopropylmethyl)- N-(2,4-dih...)
Affinity DataKi:  0.400nMAssay Description:δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures were conducted as follows. Radioligand dose-displace...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309366((2R,3aS,4R,9bS)-methyl-12- (cyclopropylmethyl)-3a,...)
Affinity DataKi:  0.530nMAssay Description:δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures were conducted as follows. Radioligand dose-displace...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309415((2S,3aS,4R,9bS)-12-(cyclopropylmethyl)- 3a,8-dihyd...)
Affinity DataKi:  0.640nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309408((2R,3aS,4R,9bS)-N-benzyl-12- (cyclopropylmethyl)-3...)
Affinity DataKi:  0.75nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309406((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- 3a,8-dihyd...)
Affinity DataKi:  0.840nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236819(US9388162, 9)
Affinity DataKi:  0.970nM ΔG°:  -51.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309408((2R,3aS,4R,9bS)-N-benzyl-12- (cyclopropylmethyl)-3...)
Affinity DataKi:  1.39nMAssay Description:δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures were conducted as follows. Radioligand dose-displace...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236866(US9388162, 73)
Affinity DataKi:  1.98nM ΔG°:  -53.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236819(US9388162, 9)
Affinity DataKi:  6.18nM ΔG°:  -50.8kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236867(US9388162, 74)
Affinity DataKi:  7.42nM ΔG°:  -50.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309416((2S,3aS,4R,9bS)-3a,8-dihydroxy-12- methyl-N-phenet...)
Affinity DataKi:  9.29nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309406((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- 3a,8-dihyd...)
Affinity DataKi:  10.2nMAssay Description:δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures were conducted as follows. Radioligand dose-displace...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309374((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- 3a,8-dihyd...)
Affinity DataKi:  17.3nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309329((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- N-(2-guani...)
Affinity DataKi:  19.7nMAssay Description:δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures were conducted as follows. Radioligand dose-displace...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309331((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- N-(4-guani...)
Affinity DataKi:  23.6nMAssay Description:δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures were conducted as follows. Radioligand dose-displace...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM162697(US9056836, 11 | US9056836, 11/13 | US9056836, 13)
Affinity DataKi:  33.1nM ΔG°:  -42.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM162698(US9056836, 12)
Affinity DataKi:  42.5nM ΔG°:  -42.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309374((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- 3a,8-dihyd...)
Affinity DataKi:  55.6nMAssay Description:δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures were conducted as follows. Radioligand dose-displace...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM162696(US9056836, 10)
Affinity DataKi:  64.5nM ΔG°:  -41.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236829(US9388162, 48)
Affinity DataKi:  65.3nM ΔG°:  -41.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM162697(US9056836, 11 | US9056836, 11/13 | US9056836, 13)
Affinity DataKi:  66.8nM ΔG°:  -41.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM228518(US9340542, 8)
Affinity DataKi:  72.5nMpH: 7.4Assay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM162701(US9056836, 22)
Affinity DataKi:  79.1nM ΔG°:  -40.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236865(US9388162, 72)
Affinity DataKi:  82.9nM ΔG°:  -40.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM162700(US9056836, 19)
Affinity DataKi:  89.6nM ΔG°:  -40.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236825(US9388162, 17)
Affinity DataKi:  128nM ΔG°:  -39.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236827(US9388162, 19)
Affinity DataKi:  146nM ΔG°:  -39.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM228515(US9340542, 7)
Affinity DataKi:  148nMpH: 7.4Assay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM228520(US9340542, 9)
Affinity DataKi:  148nMpH: 7.4Assay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM309360((2R,3aS,4R,9bS)-12-(cyclopropylmethyl)- 3a-hydroxy...)
Affinity DataKi:  182nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236823(US9388162, 15)
Affinity DataKi:  191nM ΔG°:  -38.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236829(US9388162, 48)
Affinity DataKi:  223nM ΔG°:  -41.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236839(US9388162, 24)
Affinity DataKi:  249nM ΔG°:  -37.7kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236818(US9388162, 8)
Affinity DataKi:  261nM ΔG°:  -37.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236830(US9388162, 49)
Affinity DataKi:  324nM ΔG°:  -37.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236828(US9388162, 46)
Affinity DataKi:  394nM ΔG°:  -36.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236817(US9388162, 1)
Affinity DataKi:  408nM ΔG°:  -36.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM228518(US9340542, 8)
Affinity DataKi:  473nM ΔG°:  -36.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236865(US9388162, 72)
Affinity DataKi:  476nM ΔG°:  -39.1kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236828(US9388162, 46)
Affinity DataKi:  591nM ΔG°:  -38.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM162697(US9056836, 11 | US9056836, 11/13 | US9056836, 13)
Affinity DataKi:  621nM ΔG°:  -38.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membran...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM236839(US9388162, 24)
Affinity DataKi:  668nM ΔG°:  -38.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 470 total ) | Next | Last >>
Jump to: